The effect of β-receptor blockade on factor VIII levels and thrombin generation in patients with venous thromboembolism

Thrombosis and Haemostasis

Volumn 89, Issue 5, 2003, Pages 837-841

  Schönauer, Verena ^a   Giannini, Sandra ^a   Christ, Günter ^a   Quehenberger, Peter ^a   Bieglmayer, Christian ^a   Stain, Milena ^a   Kyrle, Paul A ^a   Weltermann, Ansgar ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Factor VIII; Thrombin generation; Venous Thrombosis; Receptor blockade

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 8; PROPRANOLOL; THROMBIN ANTITHROMBIN COMPLEX; VASOPRESSIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; HEMOSTASIS; HUMAN; HYPOTHESIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; SKIN INCISION; STATISTICAL ANALYSIS; THROMBIN TIME; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS BLOOD;

EID: 0037954287     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613470     Document Type: Article

References (23)

1. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
2. O'Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: Role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997; 77: 825-8.
3. O'Donnell J, Mumford AD, Manning RA, Laffan M. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 2000; 83: 10-3.
4. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-62.
5. Kraaijenhagen RA, In't-Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
6. Kamphuisen PW, Eikenboom JCJ, Vos HL, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reaction. Thromb Haemost 1999; 81: 680-3.
7. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279: 458-62.
8. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 1998; 114: 511S-23S.
9. Small M, Tweddel AC, Rankin AC, Lowe GD, Prentice CR, Forbes CD. Blood coagulation and platelet function following maximal exercise: Effects of beta-adrenoceptor blockade. Haemostasis 1984; 14: 262-8.
10. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93.
11. Mannucci PM. Enhancement of plasminogen activator by vasopressin and adrenaline: A role of cyclic AMP? Thromb Res 1974; 4: 539-49.
12. Cohen RJ, Epstein SE, Cohen LS, Dennis LH. Alterations of fibrinolysis and blood coagulation induced by exercise, and the role of beta-adrenergic-receptor stimulation. Lancet 1968; 2: 1264-6.
13. Kraaijenhagen RA, Hoppener MR, Levi M, Büller HR. Beta-receptor blockade decreases elevated plasma levels of factor VIIIc in patients with deep vein thrombosis. The etiology of this important risk factor revealed? Blood 2000; 96: 450a
14. Mielke C-HJ, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969; 34: 204-15.
15. Bauer KA, Barzegar S, Rosenberg RD. Influence of anticoagulants used for blood collection on plasma prothrombin fragment F1 + 2 measurements. Thromb Res 1991; 63: 617-28.
16. Mannucci PM, Tripodi A, Bottasco B, et al. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost 1992; 67: 200-2.
17. Zoller B, Holm J, Svensson P, Dahlback B. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost 1996; 75: 270-4.
18. Simioni P, Scarano L, Gavasso S, et al. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br J Haematol 1996; 92: 435-41.
19. Martinelli I, Bottasco B, Duca F, Faioni E, Mannucci PM. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost 1996; 75: 703-5.
20. Kyrle PA, Eichinger S, Pabinger I, et al. Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism. Thromb Haemost 1997; 77: 829-33.
21. O'Donnell J, Mumford AD, Manning RA, Laffan MA. Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br J Haematol 2001; 115: 687-91.
22. Eichinger S, Wolzt M, Schneider B, et al. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet-activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin). Arterioscler Thromb Vasc Biol 1995; 15: 886-92.
23. Eichinger S, Wolz M, Nieszpaur-Los M, et al. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin (Fragmin) and of on coagulation activation at the site of plug formation in vivo. Thromb Haemost 1994; 72: 831-5.